Alligator Bioscience

Alligator Bioscience P/CF

The P/CF (Price-to-Cash-Flow Ratio) of Alligator Bioscience (ATORX.ST) as of Oct 21, 2026 is -0.56. In the previous year, P/CF (Price-to-Cash-Flow Ratio) was -0.41 — a change of 36.18% (lower).

P/CF

-0.56

YoY

36.18%

Last updated:

P/CF (Price-to-Cash-Flow Ratio) of Alligator Bioscience is 2025 -0.56 . P/CF (Price-to-Cash-Flow Ratio) of Alligator Bioscience was 2024 -0.41 . It decreases by 36.18% lower compared to the previous year.

The Alligator Bioscience P/CF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

P/CF
Date
P/CF
Jan 1, 2018
-0.84 SEK
Jan 1, 2019
-0.49 SEK
Jan 1, 2020
-0.62 SEK
Jan 1, 2021
-0.69 SEK
Jan 1, 2022
-0.51 SEK
Jan 1, 2023
-0.46 SEK
Jan 1, 2024
-0.41 SEK
Jan 1, 2025
-0.56 SEK
The Alligator Bioscience P/CF history
YEARP/CFYoY
-0.56+36.18%
-0.41-10.89%
-0.46-8.81%
-0.51-26.40%
-0.69+11.27%
-0.62+26.61%
-0.49-41.82%
-0.84-4.31%
-0.88-62.25%
-2.33-644.79%
0.43-130.62%
-1.40—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Alligator Bioscience Stock analysis

What does Alligator Bioscience do? Alligator Bioscience AB develops antibody-based cancer immunotherapies using its ALLIGATOR-GOLD and FIND technology platforms. The company focuses on tumor-directed immunotherapies, particularly agonistic mono- and bispecific antibodies. Its pipeline includes three projects: ADC-1013 (antibody), ATOR-1015 (bispecific immune activating antibody), and ATOR-1016 (bispecific agonistic antibody), all in research/preclinical stages. The company generates revenue through partnerships and licensing agreements with pharmaceutical companies for its antibody development platforms and pipeline candidates. Alligator Bioscience AB targets pharmaceutical companies seeking innovative immunotherapy solutions. The firm's technology platforms, ALLIGATOR-GOLD and FIND, are sold to partners for antibody discovery and optimization. Its pipeline assets, including ATOR-1015 and ATOR-1016, are licensed to partners for further development and commercialization. The company's revenue model relies on upfront payments, milestone payments, and royalties from these partnerships. The company's business model centers on leveraging its proprietary antibody platforms to create value for partners. By offering its technology for discovery and optimization, Alligator Bioscience AB enables pharmaceutical companies to accelerate their immunotherapy drug development. This approach allows the company to monetize its research without directly commercializing drugs, focusing instead on early-stage development and partnership opportunities. Alligator Bioscience is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Alligator Bioscience stock

P/CF (Price-to-Cash-Flow Ratio) of Alligator Bioscience is -0.56 in 2025.

P/CF (Price-to-Cash-Flow Ratio) of Alligator Bioscience changed from -0.41 to -0.56, representing a 36.18% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of P/CF (Price-to-Cash-Flow Ratio) Alligator Bioscience since 2006 – with annual values, charts, and detailed analysis.

The Price-to-Cash-Flow ratio measures the stock price relative to operating cash flow per share. Unlike P/E, it is harder to manipulate as cash flow is less subject to accounting adjustments.

P/CF = Stock Price / Operating Cash Flow per Share

To evaluate P/CF (Price-to-Cash-Flow Ratio)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for P/CF (Price-to-Cash-Flow Ratio).

A 'good' varies by industry and company stage. On Eulerpool, you can compare P/CF (Price-to-Cash-Flow Ratio)'s Alligator Bioscience with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Valuation — Alligator Bioscience

P/EP/SEV/EBITP/BP/CFP/FCFPEGEV/RevenueEV/EBITDAEV/FCFEarnings YieldFCF YieldMarket capitalizationEnterprise ValueForward P/EP/TBVShareholder YieldBuyback YieldDiv.-Adj. PEGEV/OCF

All Key Metrics — Alligator Bioscience